Oxurion NV

About Oxurion NV

Oxurion is a biotech research company focused on pioneering life-changing treatments to prevent blindness and enhance vision for patients worldwide. Specializing in retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD), Oxurion is committed to addressing unmet medical needs in ophthalmology. Additionally, the company aims to build an integrated group of subcontractors serving healthcare stakeholders by acquiring majority stakes in promising European pharmaceutical subcontractors, such as holding a 72% stake in Axiodis CRO.

Products & Services

Treatments for Retinal Diseases:Developing therapies targeting Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD) to prevent blindness and enhance vision.

Investment in Pharmaceutical Subcontractors:Acquiring majority stakes in European pharmaceutical subcontractors, such as Axiodis CRO (specialized in biometrics), to build an integrated group serving healthcare stakeholders.

Specialties

Retinal Diseases Geographic Atrophy (GA) Age-related Macular Degeneration (AMD) Ophthalmology Biometrics (through Axiodis CRO)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Debt T: - FT: Convertible Debt	A: 450000 MR: - FA: EUR 450,000 FAN: 450000	D: 2024-04-10 FD: 2024-04-10	1 investors
2	RT: Convertible Bonds T: - FT: Convertible Bonds	A: 300000 MR: - FA: EUR 300,000 FAN: 300000	D: 2024-03-05 FD: 2024-03-05	1 investors
3	RT: Convertible Debt T: - FT: Convertible Debt	A: 1080000 MR: - FA: EUR 1.0 million FAN: 1080000	D: 2023-06-15 FD: 2023-06-15	1 investors
4	RT: Convertible Bonds T: - FT: Convertible Bonds	A: 2160000 MR: - FA: EUR 2.0 million FAN: 2160000	D: 2023-05-22 FD: 2023-05-22	1 investors
5	RT: Convertible Bonds T: - FT: Convertible Bonds	A: 2000000 MR: - FA: EUR 2.0 million FAN: 2000000	D: 2023-04-27 FD: 2023-04-27	1 investors
6	RT: Convertible Debt T: - FT: Convertible Debt	A: 2800000 MR: - FA: EUR 2,800,000 FAN: 2800000	D: 2023-03-20 FD: 2023-03-20	1 investors
7	RT: Convertible Bonds T: - FT: Convertible Bonds	A: 21360000 MR: - FA: up to €20 million FAN: 21360000	D: 2023-03-02 FD: 2023-03-02	1 investors
8	RT: Convertible Bonds T: - FT: Convertible Bonds	A: 4332000 MR: - FA: four million euros FAN: 4332000	D: 2023-01-26 FD: 2023-01-26	1 investors
9	RT: Debt T: - FT: Debt	A: 4320000 MR: - FA: EUR 4 million FAN: 4320000	D: 2023-01-25 FD: 2023-01-25	1 investors

Convertible Debt Latest

2024-04-10

$450K

1 investor (Pro only)

Convertible Bonds 2024-03-05

$300K

Convertible Debt 2023-06-15

$1.1M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Pascal Ghoson

CEO/CFO

C

Charles Paris de Bollardière

Chairman Of The Board

J

James Hartmann

Independent Non-Executive Director

N

Nelly Souleymane

Independent Non-Executive Director

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

Oxurion NV Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised